Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden

Peeker, Ralph ; Samsioe, Göran LU ; Kowalski, Jan ; Andersson, Ann-Sofie and Bergqvist, Agneta (2010) In Scandinavian Journal of Urology and Nephrology 44(3). p.138-146
Abstract
Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6... (More)
Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p <0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
OAB-q, Antimuscarinic, health-related quality of life, overactive, bladder, tolterodine
in
Scandinavian Journal of Urology and Nephrology
volume
44
issue
3
pages
138 - 146
publisher
Taylor & Francis
external identifiers
  • wos:000277391100002
  • scopus:77954881755
  • pmid:20367449
ISSN
0036-5599
DOI
10.3109/00365591003709468
language
English
LU publication?
yes
id
375757f9-5560-44a4-b11b-5e9fc798caca (old id 1618129)
date added to LUP
2016-04-01 13:41:04
date last changed
2022-03-06 07:06:25
@article{375757f9-5560-44a4-b11b-5e9fc798caca,
  abstract     = {{Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p &lt;0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%.}},
  author       = {{Peeker, Ralph and Samsioe, Göran and Kowalski, Jan and Andersson, Ann-Sofie and Bergqvist, Agneta}},
  issn         = {{0036-5599}},
  keywords     = {{OAB-q; Antimuscarinic; health-related quality of life; overactive; bladder; tolterodine}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{138--146}},
  publisher    = {{Taylor & Francis}},
  series       = {{Scandinavian Journal of Urology and Nephrology}},
  title        = {{A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden}},
  url          = {{http://dx.doi.org/10.3109/00365591003709468}},
  doi          = {{10.3109/00365591003709468}},
  volume       = {{44}},
  year         = {{2010}},
}